Heterogeneity of βs gene haplotypes in patients with sickle cell disease (SCD) in Oman: A review of relevant publications

Main Article Content

Nawal Al-Mashaikhi https://orcid.org/0000-0003-1053-9803
Abdulhakim Al-Rawas https://orcid.org/0000-0002-1921-7395
Yasser Wali https://orcid.org/0000-0003-4275-4524
Ashraf Soliman https://orcid.org/0000-0002-7145-6561
Doaa Khater https://orcid.org/0000-0002-3377-8949


Sickle cell disease, Hb SS, genotype, phenotype, severity, HbF, Hb Sβ-thalassemia, Oman


Sickle cell disease (SCD), caused by a mutation in the β-globin gene HBB, is widely distributed in malaria endemic regions.  The prevalence of sickle cell trait and disease reaches up to 4.8–6% and 0.2% respectively, which is the highest among the Arab Gulf states.  Omani population represents a variability of HbS genotype combinations with other Hb genotypes modify the clinical severity of the disease. The most prevalent sickling abnormality in Oman is Hb S/S (SCA) followed by Hb S/β-thalassemia. Omani children with SCD with high Hb F level had less severe disease. More than two-thirds of SCD cases were running a mild course of the disease due to the high prevalence of  a-thalassemia trait. The severity index has been correlated with the early age of presentation, the absence of  a-thalassemia trait and the lower level of HbF as well as to the existence of different β-globin gene haplotypes.  S/ β0 presented with the same clinical severity of S/S while those with S/ β+ had some splenic function into adulthood and were more prone to splenic sequestration. The unique existence of HbS-Oman (a severe variant of sickle hemoglobinopathy) markedly increased the severity of the disease. Compound heterozygotes HbS-Oman resulted in very severe clinical manifestations with transfusion-dependency and hypersplenism early in life. This paper summarizes and reviews βs gene haplotypes in patients with sickle cell anemia (SCA) in Oman. (www.actabiomedica.it)


Download data is not yet available.
Abstract 56 | PDF Downloads 34


1. Daar S, Hussein H, Gravell D, Nagel R, Krishnamoorthy R. Genetic epidemiology of HbS in Oman: multicentric origin for the betaS gene. Am J Hematol 2000; 64:39-46.
2. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet 2005; 77:171-92.
3. Wali Y, AlBalushi H, Nazir HF. Sickle cell disease in Oman and HBS Oman: a brief review. Hematol Transfus Int J 2017; 4:142-3.
4. Ha J, Martinson R, Iwamoto SK, Nishi A. Hemoglobin E, malaria and natural selection. Evol Med Public Health 2019; 2019:232-41.
5. Rajab AG, Patton MA, Modell B. Study of hemoglobinopathies in Oman through a national register. Saudi Med J 2000; 21:1168-72.
6. Al-Riyami A, Ebrahim GJ. Genetic Blood Disorders Survey in the Sultanate of Oman. J Trop Pediatr 2003;49 Suppl 1:1-20.
7. Alkindi S, Al Zadjali S, Al Madhani A, et al. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates. Hemoglobin 2010; 34:135-44.
8. Al Zeedi MASA, Al Abri ZG. Attitudes and impact among people with abnormal premarital screening test results in Muscat governorate's primary healthcare centers in 2018. J Community Genet 2021; 12:163-9.
9. Al-Riyami AA, Suleiman AJ, Afifi M, Al-Lamki ZM, Daar S.A community-based study of common hereditary blood disorders in Oman. East Mediterr Health J 2001; 7:1004-11.
10. Alkindi S, Al Zadjali S, Al Madhani A, et al. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates. Hemoglobin 2010; 34:135-44.
11. Hassan, S., Muslahi, M. , Riyami, M., et al. (2015). Haplotypes, Sub-Haplotypes and Geographical Distribution in Omani Patients with Sickle Cell Disease. Thalassemia Reports 2015; 5: doi.org/10.4081/thal.2015.4739.
12. Hassan SM, Hamza N, Jaffer Al-Lawatiya F, et al. Extended molecular spectrum of β-and α-thalassemia in Oman. Hemoglobin 2010; 34:127-34.
13. Al-Lamki Z, Wali YA, Wasifuddin MS, et al. Natural History of Sickle hemoglobinopathy in Omani Children. Int J Paediatr Haematol Oncol 2000;7:101–7.
14. Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev 2014;15:4-12.
15. Benites BD, Bastos SO, Baldanzi G, et al. Sickle cell/β-thalassemia: Comparison of Sβ0 and Sβ+ Brazilian patients followed at a single institution. Hematology 2016;21:623-9.
16. Wali YA, Al-Lamki Z, Hussein SS, et al. Splenic function in omani children with sickle cell disease: correlation with severity index, hemoglobin phenotype, iron status, and -thalassemia trait. Pediatr Hematol Oncol 2002; 19:491–500.
17. Adekile AD, Tuli M, Haider MZ, Al-Zaabi K, Mohannadi S, Owunwanne A. Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Am J Hematol 1996; 53:1-5.
18. Langdown JV, Williamson D, Knight CB, Rubenstein D, Carrell RW. A new doubly substituted sickling haemoglobin: HbS-Oman. Br J Haematol 1989; 71:443–4.
19. Al-Balushi HWM, Wali Y, Al Awadi M, et al. The super sickling haemoglobin HbS-Oman: a study of red cell sickling, K+ permeability and associations with disease severity in patients heterozygous for HbA and HbS-Oman (HbA/S-Oman genotype). Br J Haematol 2017; 179:256-65.
20. Suresh V, Asila NS, Nafisa MZ, Laitha MN, Susamma M. Haemoglobin S Oman trait- A sickling variant. Oman Med J 1999; 16:23–4.
21. Al Jahdhamy R, Makki H, Farrell G, Al Azzawi S. A case of compound heterozygosity for Hb S and Hb S Oman. Br J Haematol 2002; 116:504.
22. Knox-Macaulay HH, Ahmed MM, Gravell D, Al-Kindi S, Ganesh A. Sickle cell-haemoglobin E (HbSE) compound heterozygosity: a clinical and haematological study. Int J Lab Hematol 2007; 29:292-301.
23. Thalagahage KH, Jayaweera JAAS, Kumbukgolla W, et al. HbS/D-Punjab Disease: Report of 3 Cases from Sri Lanka. Indian J Hematol Blood Transfus 2018; 34:350-2.

Most read articles by the same author(s)